6877002
- Product Name
- 6877002
- CAS No.
- 433249-94-6
- Chemical Name
- 6877002
- Synonyms
- 6877002;Compound 6877002;TRAF-STOP 6877002;CD40-TRAF6 inhibitor;CD40-TRAF6 signaling inhibitor;CD40-TRAF6 Signaling Inhibitor, 6877002;TRAF-STOP inhibitor 6877002, 10 mM in DMSO;Compound 6877002, CD40-TRAF6 interaction inhibitor;3-((2,5-Dimethylphenyl)amino)-1-phenylprop-2-en-1-one;2-Propen-1-one, 3-[(2,5-dimethylphenyl)amino]-1-phenyl-
- CBNumber
- CB03311729
- Molecular Formula
- C17H17NO
- Formula Weight
- 251.32
- MOL File
- 433249-94-6.mol
6877002 Property
- Boiling point:
- 378.6±42.0 °C(Predicted)
- Density
- 1.104±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO: 125 mg/mL (497.37 mM)
- pka
- 0.82±0.70(Predicted)
- form
- Solid
- color
- Light yellow to yellow
N-Bromosuccinimide Price
- Product number
- SML1160
- Product name
- CD40-TRAF6 signaling inhibitor
- Purity
- ≥98% (HPLC)
- Packaging
- 5 mg
- Price
- $99.75
- Updated
- 2025/07/31
- Product number
- SML1160
- Product name
- CD40-TRAF6 signaling inhibitor
- Purity
- ≥98% (HPLC)
- Packaging
- 25 mg
- Price
- $332
- Updated
- 2025/07/31
- Product number
- D457460
- Product name
- 3-[(2,5-Dimethylphenyl)amino]-1-phenyl-2-propen-1-one
- Packaging
- 50mg
- Price
- $320
- Updated
- 2021/12/16
- Product number
- D457460
- Product name
- 3-[(2,5-Dimethylphenyl)amino]-1-phenyl-2-propen-1-one
- Packaging
- 250mg
- Price
- $1235
- Updated
- 2021/12/16
- Product number
- CS-0033112
- Product name
- TRAF-STOPinhibitor6877002
- Purity
- 99.89%
- Packaging
- 5mg
- Price
- $50
- Updated
- 2021/12/16
6877002 Chemical Properties,Usage,Production
Uses
3-[(2,5-Dimethylphenyl)amino]-1-phenyl-2-propen-1-one functions as CD40-TRAF6 inhibitors. Inhibition of CD40 signalling pathway seems a better way to ameliorate inflammatory diseases, like the inflammation in models of peritonitis and sepsis.
Biological Activity
Cell permeable: yes', 'Primary Target
TRAF6
in vivo
TRAF-STOP inhibitor 6877002 (10 μmol/kg; intraperitoneal injection; once a day; 6 weeks) retards the development of early atherosclerosis and reduces atherosclerotic plaque area in apolipoprotein E-deficient (Apoe-/-) mice[1].
TRAF-STOP inhibitor 6877002 (10 μmol/kg; intraperitoneal injection; once a day; 6 weeks) halts the progression of established atherosclerosis, induces a stable plaque phenotype, reduces macrophage number and proliferation, decreases the size of necrotic cores, reduces the number of neutrophils and T cells, and increases collagen and αSMA+ smooth muscle cell content in atherosclerotic plaques in apolipoprotein E-deficient (Apoe-/-) mice[1].
TRAF-STOP inhibitor 6877002 (10 μmol/kg; administered via recombinant high-density lipoprotein nanoparticles; twice a week; 6 weeks) reduces plaque volume in the aortic root and the number of macrophages in plaques in apolipoprotein E-deficient (Apoe-/-) mice[1].
| Animal Model: | Male apolipoprotein E-deficient (Apoe-/-) mice (22 weeks old), with advanced atherosclerotic lesions already present in the aortic arch to establish an established atherosclerosis model[1]. |
| Dosage: | 10 μmol/kg (vehicle: PBS, 0.05% Tween 80, 5% dimethylsulfoxide) |
| Administration: | Intraperitoneal injection, once a day, for 6 weeks |
| Result: | Halted the progression of established atherosclerosis, reduced the total atherosclerotic plaque area in the aortic arch and aortic root. The atherosclerotic plaques exhibited a stable phenotype with decreased macrophage number and proliferation, smaller necrotic cores, fewer neutrophils and T cells, and increased collagen and αSMA+ smooth muscle cell content. |
| Animal Model: | Male apolipoprotein E-deficient (Apoe-/-) mice (12 weeks old), fed a normal chow diet to establish an atherosclerosis-prone model[1]. |
| Dosage: | 10 μmol/kg (vehicle: PBS, 0.05% Tween 80, 5% dimethylsulfoxide) |
| Administration: | Intraperitoneal injection, once a day, for 6 weeks |
| Result: | Retarded the development of early atherosclerosis, reduced atherosclerotic plaque area in the aortic arch, and the plaques contained fewer macrophages, T cells, and neutrophils. There were no changes in the number of proliferating or apoptotic cells, plaque smooth muscle cell or collagen content. |
| Animal Model: | Male apolipoprotein E-deficient (Apoe-/-) mice (12 weeks old) with atherosclerosis model[1]. |
| Dosage: | 10 μmol/kg (packaged in recombinant high-density lipoprotein nanoparticles) |
| Administration: | Administered via recombinant high-density lipoprotein nanoparticles, twice a week, for 6 weeks |
| Result: | Reduced plaque volume in the aortic root and the number of macrophages in plaques. |
storage
Store at +4°C
6877002 Preparation Products And Raw materials
Raw materials
Preparation Products
6877002 Suppliers
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 12952
- Advantage
- 65
- Tel
- 400-400-164-7117 18317119277
- Fax
- +86-21-61629029
- product02@bidepharm.com
- Country
- China
- ProdList
- 39967
- Advantage
- 60
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9803
- Advantage
- 58
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 021-QQ：65489617 15618227136
- Fax
- 21-5161 9052
- Sales@ATKchemical.com
- Country
- China
- ProdList
- 9166
- Advantage
- 58
- Tel
- 010-50973130 18101056239
- 3193328036@qq.com
- Country
- China
- ProdList
- 29759
- Advantage
- 68
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32470
- Advantage
- 58
- Tel
- +86-0519-85788828 +86-13775037613
- sales@chemrenpharm.com
- Country
- China
- ProdList
- 4023
- Advantage
- 58
- Tel
- 18818260767
- Fax
- QQ 3610331285
- sales@chemegen.com
- Country
- China
- ProdList
- 11218
- Advantage
- 58
- Tel
- 88888888888
- hongquchem@qq.com
- Country
- China
- ProdList
- 5132
- Advantage
- 58